ACAD vs GS · P/E 15, rev $576.0M vs P/E 20, rev $37.56B
ACADIA Pharmaceuticals Inc (ACAD) versus Goldman Sachs Group Inc (GS) — a side-by-side from cached financials, not a winner call.
ACADIA Pharmaceuticals Inc (ACAD) is a biotechnology company listed on US.
Goldman Sachs Group Inc (GS) is a capital markets company listed on NYSE. It is led by David Solomon.
Latest reported ACAD revenue for 2026-06-30 was $576.0M. Net income was $35.1M. ACAD currently screens at market cap $3.51B and trailing P/E 15.3.
Latest reported GS revenue for 2026-06-30 was $37.56B. Net income was $12.26B. GS currently screens at market cap $324.25B and trailing P/E 20.1.
ACAD currently screens at market cap $3.51B and trailing P/E 15.3. GS currently screens at market cap $324.25B and trailing P/E 20.1.
Not investment advice. Open the ACAD and GS stock pages for the full models.
Not investment advice.